19 September 2018 - Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus everolimus in the phase 3 pivotal METEOR trial.

Exelixis today announced that its partner Ipsen has received approval from Health Canada of Cabometyx (cabozantinib) tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy. 

Health Canada granted Cabometyx priority review status, which provided an accelerated review of Ipsen’s new drug submission.

Read Exelixis press release